• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search

Impact of RBX2660 on the Intestinal Microbiota of Patients with Recurrent Clostridium difficile Infection Enrolled in the Randomized, Placebo-Controlled PUNCH CD 2 Trial

Courtney Jones, BS; Bill Shannon, PhD, MBA; Sharina Carter, BS

Download this poster (1.2 MB)
Download the abstract (43 KB)

Infectious Diseases Week (ID Week)
October 26-30, 2016, New Orleans, LA

Background

  • Perturbation of the intestinal microbiota, primarily by antibiotics, is a risk factor for Clostridium difficile infection (CDI).
  • Restoration of a variable intestinal microbiota protects against recurrence of CDI.
  • RBX2660 is a microbiota-based drug under study for the prevention of recurrent CDI.
  • We evaluated the impact of RBX2660 treatment on the intestinal microbiota of patients enrolled in the PUNCH CD 2 trial, a multicenter, randomized, double-blinded, placebo controlled phase 2b study.

Methods

  • Patients in the 3-arm PUNCH CD 2 trial were randomized 1:1:1 to receive either: 2 doses of RBX2660 (Group A); 2 doses of placebo (Group B); or 1 dose of RBX2660 and 1 dose of placebo (Group C). Success was defined as the absence of Clostridium difficile -associated diarrhea at 8 weeks following completion of the last treatment.
  • Failure was defined as recurrence of CDI symptoms; a positive stool test; a need for CDI retreatment; and no other cause for CDI symptoms within 8 weeks.
  • Longitudinal 16s rRNA analysis using the Illumina MiSeq platform was performed on a total of 120 stool samples from patients in the 3 arms of the study (Group A: n=23; Group B: n=22; Group C: n= 22) at baseline, 7 days and 30 days after the second blinded dose.
  • The variable region V4 was targeted to identify the operational taxonomic units (OTUs) in each sample.

Results

  • At baseline, the microbiota profiles were similar across all samples.
  • OTU analysis demonstrated higher diversity between baseline and follow-up time points for all patients who responded successfully to their assigned treatment.
  • The higher diversity at follow-up points was also true for placebo responders (12 patients in Group B who received two doses of placebo and did not experience recurrent CDI symptoms prior to 8-week follow-up).
  • Specifically, successful Group A patients had an increase in Akkermansia and Bacteroides from baseline; successful Group B and C patients had a decreased abundance of Enterobacter (Figures 1-3).
  • Of the three groups of patients, those in Group A (two doses of active treatment) showed the greatest increase in bacterial diversity (number of OTUs) and abundance of taxa between baseline and all follow-up points (Figure 4).

Conclusions

  • In this randomized, placebo-controlled study of RBX2660 for recurrent CDI, 16s rRNA analysis found that patients who succeeded with their assigned therapy had a more diverse intestinal microbiota at 7 and 30 days compared with baseline.

Microbiota Restoration Therapy Abstracts, Microbiota Restoration Therapy Posters Abstracts, Posters

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us